TapewireFind a company

person · Reporting owner

Gutry Phil

Disclosed activity across 2 companies

Tapewire entity
128068
SEC CIK
0001653224

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Avalo Therapeutics, Inc.

Report date December 01, 2021 · Filed December 04, 2021

Section 16 reporting ended · disclosed 2021-12-04. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

LENZ Therapeutics, Inc.

Report date April 11, 2022 · Filed April 13, 2022

Section 16 reporting ended · disclosed 2022-04-13. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect299,941 Reported balance After 2022-04-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2022-04-11 · Purchase · Acquired 5,000 · Balance 299,941

F1: Includes 1,470 shares acquired under the Graphite Bio, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c).

Filing footnotes · ownership attribution and instrument terms

F1: Includes 1,470 shares acquired under the Graphite Bio, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c).

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 11, 2022 Filed Apr 13, 2022 23:35 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 PurchaseCommon Stock 5,000 $4.01 $20,050.00
Disclosure

SEC source: 0001209191-22-024362 · doc4.xml · nonDerivative · entry 1

Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 299,941

F1 · balance_after: Includes 1,470 shares acquired under the Graphite Bio, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c).

Read SEC document
February 16, 2022 Filed Feb 18, 2022 23:56 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 GrantStock Option (right to buy) · Derivative 115,000 $0.00 Strike: $11.02 $0.00
Disclosure

SEC source: 0001209191-22-011465 · doc4.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 115,000 shares

Expires 2032-02-15

F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
September 30, 2021 Filed Oct 4, 2021 20:45 UTC Avalo Therapeutics, Inc. AVTX · Entity 4936 GrantStock Option (Right to Buy) · Derivative 4,718 $0.00 Strike: $2.18 $0.00
Disclosure

SEC source: 0001878894-21-000011 · edgar.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,718

Underlying: Common Stock · 4,718 shares

Expires 2031-09-30

F1 · shares: 100% of this stock option will immediately vest on the date that it is granted.

Read SEC document
June 30, 2021 Filed Jul 2, 2021 20:06 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 3,142 $0.00 Strike: $3.27 $0.00
Disclosure

SEC source: 0001192482-21-000600 · edgar.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,142

Underlying: Common Stock · 3,142 shares

Expires 2031-06-30

F1 · shares: 100% of this stock option will immediately vest on the date that it is granted.

Read SEC document
June 29, 2021 Filed Jul 1, 2021 23:00 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 ConversionSeries B Preferred Stock · Derivative 19,763 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 10

Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,126 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F3 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F3 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

Read SEC document
June 29, 2021 Filed Jul 1, 2021 23:00 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 ConversionCommon Stock 8,126 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-027016 · doc4.xml · nonDerivative · entry 3

Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 293,471

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

Read SEC document
June 15, 2021 Filed Jun 17, 2021 20:41 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $3.56 $0.00
Disclosure

SEC source: 0001192482-21-000524 · edgar.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2031-06-15

F1 · shares: This stock option will be fully vested and exercisable on June 15, 2022, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
April 18, 2021 Filed Jul 1, 2021 23:00 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 Exercise / conversionStock Option (right to buy) · Derivative 3,383 $0.00 Strike: $6.11 $0.00
Disclosure

SEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 9

Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,027

Underlying: Common Stock · 3,383 shares

Expires 2031-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F5 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

Read SEC document
April 18, 2021 Filed Jul 1, 2021 23:00 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 Exercise / conversionCommon Stock 3,383 $6.11 $20,670.13
Disclosure

SEC source: 0000899243-21-027016 · doc4.xml · nonDerivative · entry 2

Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,345

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F2 · price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

Read SEC document
March 31, 2021 Filed Apr 2, 2021 20:25 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 3,783 $0.00 Strike: $3.02 $0.00
Disclosure

SEC source: 0001653224-21-000001 · edgar.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,783

Underlying: Common Stock · 3,783 shares

Expires 2031-03-31

F1 · shares: 100% of this stock option will immediately vest on the date that it is granted.

Read SEC document
March 17, 2021 Filed Jul 1, 2021 23:00 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 GrantStock Option (right to buy) · Derivative 69,604 $0.00 Strike: $6.11 $0.00
Disclosure

SEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 8

Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,604

Underlying: Common Stock · 69,604 shares

Expires 2031-03-16

F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F6 · derivative.exercise_date: The option was granted subject to the achievement by the Company of performance vesting criteria. On June 29, 2021 the performance vesting criteria was met such that the option became reportable. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

Read SEC document
March 17, 2021 Filed Jul 1, 2021 23:00 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 GrantStock Option (right to buy) · Derivative 162,410 $0.00 Strike: $6.11 $0.00
Disclosure

SEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 7

Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,410

Underlying: Common Stock · 162,410 shares

Expires 2031-03-16

F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F5 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

Read SEC document
March 11, 2021 Filed Jul 1, 2021 23:00 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 GrantSeries B Preferred Stock · Derivative 19,763 $5.06 $100,000.78
Disclosure

SEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 6

Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,763

Underlying: Common Stock · 8,126 shares

Expires not disclosed

F3 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F3 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F3 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

Read SEC document
January 15, 2021 Filed Jul 1, 2021 23:00 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 Exercise / conversionStock Option (right to buy) · Derivative 91,406 $0.00 Strike: $0.30 $0.00
Disclosure

SEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 5

Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 91,406 shares

Expires 2031-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F4 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 5, 2020, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase.

F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

Read SEC document
January 15, 2021 Filed Jul 1, 2021 23:00 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 Exercise / conversionCommon Stock 91,406 $0.30 $27,421.80
Disclosure

SEC source: 0000899243-21-027016 · doc4.xml · nonDerivative · entry 1

Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 281,962

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F2 · price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

Read SEC document
January 13, 2021 Filed Jul 1, 2021 23:00 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 GrantStock Option (right to buy) · Derivative 91,406 $0.00 Strike: $0.30 $0.00
Disclosure

SEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 4

Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,406

Underlying: Common Stock · 91,406 shares

Expires 2031-01-12

F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F4 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 5, 2020, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase.

F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.

Read SEC document
December 31, 2020 Filed Jan 5, 2021 21:17 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 3,877 $0.00 Strike: $2.64 $0.00
Disclosure

SEC source: 0001192482-21-000032 · edgar.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,877

Underlying: Common Stock · 3,877 shares

Expires 2030-12-31

F1 · shares: 100% of this stock option will immediately vest on the date that it is granted.

Read SEC document
September 30, 2020 Filed Oct 1, 2020 20:43 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 4,516 $0.00 Strike: $2.28 $0.00
Disclosure

SEC source: 0001192482-20-000759 · edgar.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,516

Underlying: Common Stock · 4,516 shares

Expires 2030-09-30

F1 · shares: 100% of this stock option will immediately vest on the date that it is granted.

Read SEC document
June 30, 2020 Filed Jul 1, 2020 21:49 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 3,812 $0.00 Strike: $2.60 $0.00
Disclosure

SEC source: 0001192482-20-000595 · edgar.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,812

Underlying: Common Stock · 3,812 shares

Expires 2030-06-30

F1 · shares: 100% of this stock option will immediately vest on the date that it is granted.

Read SEC document
June 18, 2020 Filed Jun 19, 2020 20:11 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $2.51 $0.00
Disclosure

SEC source: 0001192482-20-000544 · edgar.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-06-18

F1 · shares: This stock option will be fully vested and exercisable on June 18, 2021, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
March 31, 2020 Filed Apr 2, 2020 20:49 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 4,310 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001578563-20-000008 · primary_doc.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,310

Underlying: Common Stock · 4,310 shares

Expires 2030-03-31

F1 · derivative.exercise_date: The stock option is fully vested.

Read SEC document
December 31, 2019 Filed Jan 2, 2020 21:56 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 2,375 $0.00 Strike: $5.39 $0.00
Disclosure

SEC source: 0001578563-20-000001 · primary_doc.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,375

Underlying: Common Stock · 2,375 shares

Expires 2029-12-31

F1 · derivative.exercise_date: The stock option is fully vested.

Read SEC document
September 30, 2019 Filed Oct 2, 2019 20:30 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 3,907 $0.00 Strike: $3.29 $0.00
Disclosure

SEC source: 0001578563-19-000026 · primary_doc.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,907

Underlying: Common Stock · 3,907 shares

Expires 2029-09-30

F1 · derivative.exercise_date: The stock option is fully vested.

Read SEC document
August 07, 2019 Filed Oct 3, 2019 21:20 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $2.93 $0.00
Disclosure

SEC source: 0001578563-19-000030 · primary_doc.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2029-08-07

F1 · derivative.exercise_date: The stock option will vest in full on August 7, 2020, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 28, 2019 Filed Jul 2, 2019 20:08 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 2,323 $0.00 Strike: $5.44 $0.00
Disclosure

SEC source: 0001104659-19-039024 · a4.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,323

Underlying: Common Stock · 2,323 shares

Expires 2029-06-28

Read SEC document
March 29, 2019 Filed Apr 1, 2019 19:39 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantEmployee Stock Option (Right to Buy) · Derivative 1,916 $0.00 Strike: $5.84 $0.00
Disclosure

SEC source: 0001562180-19-002071 · primarydocument.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,916

Underlying: Common Stock · 1,916 shares

Expires 2029-03-29

Read SEC document
December 31, 2018 Filed Jan 2, 2019 21:29 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 3,439 $0.00 Strike: $3.23 $0.00
Disclosure

SEC source: 0001578563-19-000002 · primary_doc.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,439

Underlying: Common Stock · 3,439 shares

Expires 2028-12-30

Read SEC document
September 28, 2018 Filed Oct 1, 2018 18:16 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantEmployee Stock Option (Right to Buy) · Derivative 2,351 $0.00 Strike: $4.67 $0.00
Disclosure

SEC source: 0001562180-18-004061 · primarydocument.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,351

Underlying: Common Stock · 2,351 shares

Expires 2028-09-28

Read SEC document
June 29, 2018 Filed Jul 2, 2018 21:28 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantEmployee Stock Option (Right to Buy) · Derivative 2,544 $0.00 Strike: $4.34 $0.00
Disclosure

SEC source: 0001562180-18-003173 · primarydocument.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,544

Underlying: Common Stock · 2,544 shares

Expires 2028-06-29

Read SEC document
May 15, 2018 Filed May 17, 2018 23:34 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantStock Option (Right to Buy) · Derivative 8,357 $0.00 Strike: $3.71 $0.00
Disclosure

SEC source: 0001578563-18-000008 · primary_doc.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,357

Underlying: Common Stock · 8,357 shares

Expires 2028-05-14

F1 · derivative.exercise_date: The stock options will vest in full on May 15, 2019, subject to the grantee's continued service on such vesting date.

Read SEC document
March 31, 2018 Filed Apr 4, 2018 18:36 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantEmployee Stock Option (Right to Buy) · Derivative 2,350 $0.00 Strike: $4.29 $0.00
Disclosure

SEC source: 0001562180-18-001830 · primarydocument.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,350

Underlying: Common Stock · 2,350 shares

Expires 2028-03-30

Read SEC document
December 31, 2017 Filed Jan 4, 2018 15:21 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantEmployee Stock Option (Right to Buy) · Derivative 3,179 $0.00 Strike: $3.20 $0.00
Disclosure

SEC source: 0001562180-18-000179 · primarydocument.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,179

Underlying: Common Stock · 3,179 shares

Expires 2027-12-30

Read SEC document
September 30, 2017 Filed Oct 4, 2017 18:24 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantEmployee Stock Option (Right to Buy) · Derivative 10,600 $0.00 Strike: $0.85 $0.00
Disclosure

SEC source: 0001562180-17-003189 · primarydocument.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,600

Underlying: Common Stock · 10,600 shares

Expires 2027-09-29

Read SEC document
June 30, 2017 Filed Jul 5, 2017 17:40 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantEmployee Stock Option (Right to Buy) · Derivative 14,224 $0.00 Strike: $0.57 $0.00
Disclosure

SEC source: 0001562180-17-002386 · primarydocument.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,224

Underlying: Common Stock · 14,224 shares

Expires 2027-06-29

F1 · derivative.exercise_date: The stock options vested immediately and became exercisable in full upon grant on 6/30/2017.

Read SEC document
June 30, 2017 Filed Jul 31, 2017 17:38 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantEmployee Stock Option (Right to Buy) · Derivative 8,357 $0.00 Strike: $0.57 $0.00
Disclosure

SEC source: 0001562180-17-002533 · primarydocument.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,357

Underlying: Common Stock · 8,357 shares

Expires 2027-06-29

F1 · derivative.exercise_date: The stock options will vest in full on June 30, 2018, subject to the grantees continued service on such vesting date.

Read SEC document
March 31, 2017 Filed Apr 4, 2017 18:17 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantEmployee Stock Option (Right to Buy) · Derivative 10,131 $0.00 Strike: $0.68 $0.00
Disclosure

SEC source: 0001562180-17-001405 · primarydocument.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,131

Underlying: Common Stock · 10,131 shares

Expires 2027-03-30

Read SEC document
December 31, 2016 Filed Jan 4, 2017 19:55 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantEmployee Stock Option (Right to Buy) · Derivative 3,793 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001562180-17-000141 · primarydocument.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,793

Underlying: Common Stock · 3,793 shares

Expires 2026-12-30

F1 · derivative.exercise_date: The stock options immediately vested and became exercisable in full upon grant on December 31, 2016.

Read SEC document
September 30, 2016 Filed Oct 3, 2016 19:11 UTC Avalo Therapeutics, Inc. CERC · Entity 4936 GrantEmployee Stock Option (Right to Buy) · Derivative 886 $0.00 Strike: $4.23 $0.00
Disclosure

SEC source: 0001179110-16-030161 · edgar.xml · derivative · entry 1

Gutry Phil · CIK 0001653224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 886

Underlying: Common Stock · 886 shares

Expires 2026-09-29

F1 · derivative.exercise_date: The stock options immediately vested and became exercisable in full upon grant on September 30, 2016.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.